ischemic stroke. Cerebral infarction
Conditions
Interventions
Intervention 1: Control group: In the control group, patients will receive placebo at the dose of 1 g, three times a day (every 8 hours) for 3 days in addition to the standard treatment. Intervention
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: age 18 to 85 years focal neurological disorder Clinical diagnosis of hemispheric acute ischemic stroke Radiological findings in MRI and CT scan consistent with clinical diagnosis of acute hemispheric stroke No other inflammatory disease at same time Not using other drugs that alter the level of outcomes of this study no Pregnancy and lactation Patients who have been admitted for the first 24 hours after the stroke. Patients who have had an ischemic stroke for the first time.
Exclusion criteria
Exclusion criteria: Existing evidence show acute or chronic intracerebral hemorrhage and brain aneurysm The presence of any other etiology except ischemia The presence of any cognitive or behavioral impairment that leads to a patient's lack of cooperation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of IL-6. Timepoint: before intervention and 3 days after intervention. Method of measurement: ELISA kit.;Serum level of TNF-alpha. Timepoint: before intervention and 3 days after intervention. Method of measurement: ELISA kit.;Serum level of NSE. Timepoint: before intervention and 3 days after intervention. Method of measurement: ELISA kit.;Serum level of ICAM-1. Timepoint: before intervention and 3 days after intervention. Method of measurement: ELISA kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: 3 days after intervention. Method of measurement: Clinical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Mehrpooya
Hamedan University of Medical Sciences
Outcome results
None listed